Seeking Alpha
 

Acceleron Pharma Inc. (XLRN)

- NASDAQ
  • Dec. 8, 2014, 12:45 PM
    | Dec. 8, 2014, 12:45 PM | 4 Comments
  • Apr. 2, 2014, 12:46 PM
    | Apr. 2, 2014, 12:46 PM | 1 Comment
  • Jan. 23, 2014, 9:12 AM
    | Jan. 23, 2014, 9:12 AM | Comment!
  • Jan. 6, 2014, 9:44 AM
    • Citi sees good things ahead for Acceleron Pharma (XLRN +2.4%) in 2014, as analyst Yaron Werber reiterates a Buy rating.
    • "In 2014 we expect multiple catalysts, extensive partnership with Celgene, and clinical data to continue to drive interest," Werber says, adding that Citi sees "data in both MDS and thalassemia [being] released at ASCO and EHA in June."
    • Price target hiked to $50 from $30.
    | Jan. 6, 2014, 9:44 AM | Comment!
  • Sep. 19, 2013, 2:36 PM
    • After pricing its IPO at $15 and upsizing its offering 5.58M shares from a prior 4.65M, Acceleron Pharma (XLRN) opened at $18.90 and is currently at $19.13, up 27.5%. That gives the drug developer a market cap of $509M.
    • Existing investor/partner Celgene (CELG -0.4%) bought 667K shares in a private placement coinciding with the IPO. The purchase raises Celgene's stake in Acceleron to 12.3%. Acceleron and Celgene teamed up in 2011 to develop the latter's ACE-536 drug, which aims to combat anemia.
    • Acceleron had $41.4M in revenue in 1H (up over 5x Y/Y), and net income of $14.7M. In addition to ACE-536, the company is working on cancer and kidney disease drugs.
    • S-1, IPO preview
    | Sep. 19, 2013, 2:36 PM | 1 Comment
Visit Seeking Alpha's
XLRN vs. ETF Alternatives
Company Description
Acceleron Pharma Inc is a biopharmaceutical company. It focuses on the discovery, development & commercialization of novel therapeutic candidates based on the mechanisms that the human body uses to regulate the growth & repair of its cells and tissues.